**Supplementary Table S3. RACIN phase I study: adverse events**

*Distribution of AEs/SAEs by Cohort (N, % - 8 patients)*

| **Adverse event Preferred Term** | **Cohort 1** | **Cohort 2** | **All patients** | **n (%) becameSAE - Grade** |
| --- | --- | --- | --- | --- |
| **Clinical investigations (37 events)** |
| Lymphocyte count decreased | 3 (37.5) | 4 (50.0) | 7 (87.5) |  |
| Weight decreased | 2 (25.0) | 3 (37.5) | 5 (62.5) |  |
| Amylase increased | 2 (25.0) | 1 (12.5) | 3 (37.5) |  |
| Lipase increased | 2 (25.0) | 1 (12.5) | 3 (37.5) |  |
| Neutrophil count decreased | 1 (12.5) | 2 (25.0) | 3 (37.5) |  |
| Platelet count decreased | 1 (12.5) | 2 (25.0) | 3 (37.5) |  |
| White blood cell count decreased | 1 (12.5) | 2 (25.0) | 3 (37.5) |  |
| Alanine aminotransferase increased | - | 2 (25.0) | 2 (25.0) |  |
| Aspartate aminotransferase increased | - | 2 (25.0) | 2 (25.0) |  |
| Blood alkaline phosphatase increased | - | 2 (25.0) | 2 (25.0) |  |
| Blood creatinine increased | - | 2 (25.0) | 2 (25.0) |  |
| CD4 lymphocytes decreased | 1 (12.5) | - | 1 (12.5) |  |
| Gamma-glutamyltransferase increased | - | 1 (12.5) | 1 (12.5) |  |
| **Gastrointestinal disorders (33 events)** |
| Diarrhoea | 2 (25.0) | 4 (50.0) | 6 (75.0) |  |
| Nausea | 1 (12.5) | 3 (37.5) | 4 (50.0) |  |
| Abdominal pain | 1 (12.5) | 2 (25.0) | 3 (37.5) |  |
| Constipation | - | 3 (37.5) | 3 (37.5) |  |
| **Autoimmune colitis\*** | **1 (12.5)** | 1 (12.5) | 2 (25.0) | ***1 (12.5) - G3*** |
| Vomiting | 1 (12.5) | 1 (12.5) | 2 (25.0) |  |
| Abdominal discomfort | - | 1 (12.5) | 1 (12.5) |  |
| Abdominal pain upper | 1 (12.5) | - | 1 (12.5) |  |
| Anorectal discomfort | - | 1 (12.5) | 1 (12.5) |  |
| Ascites | 1 (12.5) | - | 1 (12.5) |  |
| Dry mouth | 1 (12.5) | - | 1 (12.5) |  |
| Flatulence | - | 1 (12.5) | 1 (12.5) |  |
| Haemorrhoids | 1 (12.5) | - | 1 (12.5) |  |
| Ileus | - | 1 (12.5) | 1 (12.5) |  |
| Intra-abdominal haematoma | - | 1 (12.5) | 1 (12.5) |  |
| Large intestinal haemorrhage | 1 (12.5) | - | 1 (12.5) |  |
| Large intestine polyp | 1 (12.5) | - | 1 (12.5) |  |
| Pancreatitis | 1 (12.5) | - | 1 (12.5) |  |
| Stomatitis | 1 (12.5) | - | 1 (12.5) |  |
| **Metabolism and nutrition disorders (15 events)** |
| Decreased appetite | 2 (25.0) | 2 (25.0) | 4 (50.0) |  |
| Hypocalcaemia | 1 (12.5) | 2 (25.0) | 3 (37.5) |  |
| Hypophosphataemia | 1 (12.5) | 2 (25.0) | 3 (37.5) |  |
| Dehydration | - | 1 (12.5) | 1 (12.5) |  |
| Hyperglycaemia | - | 1 (12.5) | 1 (12.5) |  |
| Hypokalaemia | 1 (12.5) | - | 1 (12.5) |  |
| Hypomagnesaemia | - | 1 (12.5) | 1 (12.5) |  |
| Iron deficiency | 1 (12.5) | - | 1 (12.5) |  |
| **General disorders and administration site conditions (14 events)** |
| Fatigue | 3 (37.5) | 3 (37.5) | 6 (75.0) |  |
| Oedema peripheral | 2 (25.0) | 2 (25.0) | 4 (50.0) |  |
| Pyrexia | - | 2 (25.0) | 2 (25.0) |  |
| Chills | - | 1 (12.5) | 1 (12.5) |  |
| Influenza like illness | - | 1 (12.5) | 1 (12.5) |  |
| **Musculoskeletal and connective tissue disorders (13 events)** |
| Back pain | 1 (12.5) | 3 (37.5) | 4 (50.0) |  |
| Groin pain | 1 (12.5) | - | 1 (12.5) |  |
| Limb discomfort | - | 1 (12.5) | 1 (12.5) |  |
| Muscle spasms | - | 1 (12.5) | 1 (12.5) |  |
| Muscle tightness | - | 1 (12.5) | 1 (12.5) |  |
| Myositis | - | 1 (12.5) | 1 (12.5) |  |
| Pain in extremity | 1 (12.5) | - | 1 (12.5) |  |
| Pain in jaw | 1 (12.5) | - | 1 (12.5) |  |
| Plantar fasciitis | - | 1 (12.5) | 1 (12.5) |  |
| Torticollis | 1 (12.5) | - | 1 (12.5) |  |
| **Infections and infestations (10 events)** |
| **Urinary tract infection** | - | 3 (37.5) | 3 (37.5) | ***1 (12.5) - G3*** |
| Lung infection | 1 (12.5) | 1 (12.5) | 2 (25.0) |  |
| Cystitis | - | 1 (12.5) | 1 (12.5) |  |
| Diverticulitis | 1 (12.5) | - | 1 (12.5) |  |
| Rhinitis | - | 1 (12.5) | 1 (12.5) |  |
| Sinusitis | - | 1 (12.5) | 1 (12.5) |  |
| Viral upper respiratory tract infection | - | 1 (12.5) | 1 (12.5) |  |
| **Nervous system disorders (10 events)** |
| Headache | 1 (12.5) | 1 (12.5) | 2 (25.0) |  |
| Cognitive disorder | - | 1 (12.5) | 1 (12.5) |  |
| Dysarthria | - | 1 (12.5) | 1 (12.5) |  |
| Dysgeusia | 1 (12.5) | - | 1 (12.5) |  |
| Lumbar radiculopathy | 1 (12.5) | - | 1 (12.5) |  |
| Myoclonus | 1 (12.5) | - | 1 (12.5) |  |
| Pachymeningitis | - | 1 (12.5) | 1 (12.5) |  |
| Somnolence | 1 (12.5) | - | 1 (12.5) |  |
| Tremor | - | 1 (12.5) | 1 (12.5) |  |
| **Respiratory, thoracic and mediastinal disorders (10 events)** |
| Dyspnoea | 1 (12.5) | 1 (12.5) | 2 (25.0) |  |
| Bradypnea | 1 (12.5) | - | 1 (12.5) |  |
| Bronchial obstruction | - | 1 (12.5) | 1 (12.5) |  |
| Cough | 1 (12.5) | - | 1 (12.5) |  |
| Dysphonia | 1 (12.5) | - | 1 (12.5) |  |
| Haemoptysis | - | 1 (12.5) | 1 (12.5) |  |
| Hiccups | - | 1 (12.5) | 1 (12.5) |  |
| Pleural effusion | - | 1 (12.5) | 1 (12.5) |  |
| Productive cough | 1 (12.5) | - | 1 (12.5) |  |
| **Vascular disorders (10 events)** |
| Haematoma | 2 (25.0) | 2 (25.0) | 4 (50.0) |  |
| Hypotension | 2 (25.0) | 1 (12.5) | 3 (37.5) |  |
| Hot flush | 1 (12.5) | - | 1 (12.5) |  |
| Syncope | - | 1 (12.5) | 1 (12.5) |  |
| Thrombosis | - | 1 (12.5) | 1 (12.5) |  |
| **Skin and subcutaneous tissue disorders (8 events)** |
| Dry skin | 2 (25.0) | - | 2 (25.0) |  |
| Decubitus ulcer | 1 (12.5) | - | 1 (12.5) |  |
| Dermatitis | 1 (12.5) | - | 1 (12.5) |  |
| Hyperhidrosis | - | 1 (12.5) | 1 (12.5) |  |
| Hyperkeratosis | 1 (12.5) | - | 1 (12.5) |  |
| Rash maculo-papular | - | 1 (12.5) | 1 (12.5) |  |
| Skin exfoliation | 1 (12.5) | - | 1 (12.5) |  |
| **Psychiatric disorders (7 events)** |
| Anxiety | 1 (12.5) | 1 (12.5) | 2 (25.0) |  |
| Insomnia | 2 (25.0) | - | 2 (25.0) |  |
| Delirium | 1 (12.5) | - | 1 (12.5) |  |
| Depression | 1 (12.5) | - | 1 (12.5) |  |
| Hallucination | 1 (12.5) | - | 1 (12.5) |  |
| **Renal and urinary disorders (7 events)** |
| Dysuria | 1 (12.5) | 3 (37.5) | 4 (50.0) |  |
| Pollakiuria | - | 2 (25.0) | 2 (25.0) |  |
| Acute kidney injury | - | 1 (12.5) | 1 (12.5) |  |
| **Immune system disorders (6 events)** |
| Urticaria | 2 (25.0) | 1 (12.5) | 3 (37.5) |  |
| Autoimmune colitis\* | 1 (12.5) | 1 (12.5) | 2 (25.0) |  |
| Hypersensitivity | 1 (12.5) | - | 1 (12.5) |  |
| **Blood and lymphatic system disorders (4 events)** |
| Anaemia | 1 (12.5) | 3 (37.5) | 4 (50.0) |  |
| **Ear and labyrinth disorders (4 events)** |
| Vertigo | 1 (12.5) | 1 (12.5) | 2 (25.0) |  |
| Ear discomfort | - | 1 (12.5) | 1 (12.5) |  |
| Ear pain | - | 1 (12.5) | 1 (12.5) |  |
| **Injury, poisoning and procedural complications (4 events)** |
| Arthropod bite | 1 (12.5) | - | 1 (12.5) |  |
| Fall | - | 1 (12.5) | 1 (12.5) |  |
| Limb injury | - | 1 (12.5) | 1 (12.5) |  |
| Post procedural haematoma | - | 1 (12.5) | 1 (12.5) |  |
| **Neoplasms benign, malignant and unspecified (incl cysts and polyps) (4 events)** |
| Seborrhoeic keratosis | 1 (12.5) | 1 (12.5) | 2 (25.0) |  |
| **Malignant neoplasm progression** | 1 (12.5) | - | 1 (12.5) | ***1 (12.5) - G5*** |
| **Prostate cancer** | - | 1 (12.5) | 1 (12.5) | ***1 (12.5) - G5*** |
| **Endocrine disorders (3 events)** |
| Hyperthyroidism | 1 (12.5) | 1 (12.5) | 2 (25.0) |  |
| Hypothyroidism | - | 1 (12.5) | 1 (12.5) |  |
| **Eye disorders (2 events)** |
| Dyschromatopsia | 1 (12.5) | - | 1 (12.5) |  |
| Lacrimation increased | - | 1 (12.5) | 1 (12.5) |  |
| **Hepatobiliary disorders (2 events)** |
| Cholangitis | 1 (12.5) | - | 1 (12.5) |  |
| Hepatitis | - | 1 (12.5) | 1 (12.5) |  |
| **Cardiac disorders (1 event)** |
| **Autoimmune myocarditis** | - | 1 (12.5) | 1 (12.5) | 1 (12.5) – G4 |
| **Total events** | **85** | **119** | **204** | ***5*** |

***Note 1****: Both adverse events and serious adverse events are included.*

***Note 2****: Backbone Limiting Toxicities (BLT) are highlighted with light blue background (1 event of autoimmune myocarditis).*
*(\*) This adverse event was classified, according to MedDRA System Organ Classes (SOC), as ‘Immune system disorders’ and as ‘Gastrointestinal disorders’.*

*Patient 19F7 of cohort 1, experienced the event multiple times (classified as ‘Immune system disorders’ all of them).*

*Patient 095T of cohort 1, experienced the event multiple times (classified either as ‘Immune system disorders’ or as ‘Gastrointestinal disorders’).*

*Patient 1EEY of cohort 2, experienced the event once (classified as ‘Immune system disorders’).*

*Patient OXUL of cohort 2, experienced the event once (classified as ‘Gastrointestinal disorders’).*

*In case of multiple reports of the same AE/SAE for a particular patient, the highest grade is presented. If the same grade for the same AE/SAE is reported more than once, the one with the latest date is presented.*

*Based on this rule, we have 2 events (1 in each cohort, with the event of cohort 1 being also a SAE) classified as ‘Gastrointestinal disorders’ and 2 events (1 in each cohort) classified as ‘Immune system disorders’.*

Abbreviations: AE: adverse event, SAE: serious adverse event, n: number of patients